Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Therapeutic Choices for Psoriasis and Mental Health

J Dermatolog Treat; ePub 2018 May 14; Salame, et al

Therapeutic choices for psoriasis impact mental health outcomes, according to a recent study, which determined that biologic therapy is associated with reductions in psychological distress and depression as compared to oral therapy in the US adult moderate-to-severe psoriasis population. Researchers performed a nationwide, cross-sectional study comparing 2,303,534 (weighted) adults with moderate-to-severe psoriasis on biologic vs oral therapies and their associated mental health outcomes using the 2003-2015 Medical Expenditure Panel Survey (MEPS). Mental health outcomes were measured with the Kessler 6 (K6), a validated measure of psychological distress, and Patient Health Questionnaire 2 (PHQ2), a screening tool for depression. They found:

  • The mean K6 score for residents on biologic therapies was significantly lower than that of residents on oral therapies (2.72 vs 3.70).
  • The mean PHQ2 score for residents on biologic therapies was also significantly lower than that of residents on oral therapies (0.540 vs 0.890).
  • Based on adjusted multivariable linear regression models, biologic therapy was associated with significant reductions in K6 and PHQ2 scores compared to oral therapy.
Citation:

Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: A population-based study. [Published online ahead of print May 14, 2018]. J Dermatolog Treat. doi:10.1080/09546634.2018.1476654

This Week's Must Reads

Should Medical Coding Be Taught During Residency?, J Drugs Dermatol; 2018 Jun; Blecher, Halverstam, et al

Primary Closure Lengths in MMS Based on Cancer Type, Dermatolog Surg; ePub 2018 Jun 8; Theroux, et al

Citizen Pscientist: Important New Research Tool, Dermatol Ther (Heidelb); ePub 2018 Jun 6; Sanchez, et al

Acne Successfully Treated with Laser Combination, Dermatolog Surg; ePub 2018 Jun 5; Bakus, et al

FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7

Must Reads in Psoriasis

Citizen Pscientist: Important New Research Tool, Dermatol Ther (Heidelb); ePub 2018 Jun 6; Sanchez, et al

FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29

FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22

Therapeutic Choices for Psoriasis and Mental Health, J Dermatolog Treat; ePub 2018 May 14; Salame, et al

Dermoscopy Can Evaluate Inflammatory Dermatoses, J Clin Aesthet Dermatol; 2018 Apr 1; Cook, Hanna, et al